OR WAIT null SECS
The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
August 31, 2020
Under expanded FDA authorization, Gilead Sciences’ antiviral treatment for COVID-19 can be administered to all hospitalized patients.
How real estate can accelerate productivity as life sciences companies prioritize COVID-19 therapeutics, vaccines, and new diagnostics R&D amidst new guidelines.
August 28, 2020
In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.
August 26, 2020
The contract is valued at $106.3 million and is supported by Operation Warp Speed.
AstraZeneca has dosed the first participants in its Phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of a combination of two monoclonal antibodies (mAbs) for the prevention and treatment of COVID-19.
The European Commission (EC) and Moderna have concluded exploratory talks on the potential purchase of Moderna’s COVID-19 vaccine candidate for Europeans.
August 24, 2020
FDA issued an emergency use authorization for COVID-19 convalescent plasma treatments following a report on NIH concerns about insufficient studies and data.
Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.
The Phase II trial is a randomized, placebo-controlled, observer-blinded study that will include patients aged 18 to 84 years.
FDA announced it had issued an emergency use authorization for convalescent plasma that would make it easier to provide this treatment to COVID-19 patients.